GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » Forward Rate of Return (Yacktman) %

TYK Medicines (HKSE:02410) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. TYK Medicines's forward rate of return for was 0.00%.

The historical rank and industry rank for TYK Medicines's Forward Rate of Return (Yacktman) % or its related term are showing as below:

HKSE:02410's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 4
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


TYK Medicines Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for TYK Medicines's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TYK Medicines Forward Rate of Return (Yacktman) % Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
- - -

TYK Medicines Quarterly Data
Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Dec24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial - - - - -

Competitive Comparison of TYK Medicines's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, TYK Medicines's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TYK Medicines's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where TYK Medicines's Forward Rate of Return (Yacktman) % falls into.


;
;

TYK Medicines Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

TYK Medicines's Forward Rate of Return of Dec. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/49.15+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TYK Medicines  (HKSE:02410) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


TYK Medicines Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of TYK Medicines's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


TYK Medicines Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.
Executives
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng 2201 Interest of corporation controlled by you
Zhu Julia Ming 2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si 2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
He Chao 2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

TYK Medicines Headlines

No Headlines